IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer

Breast cancer bone metastasis is currently incurable, ~75% of patients with late-stage breast cancer develop disease recurrence in bone and available treatments are only palliative. We have previously shown that production of the pro-inflammatory cytokine interleukin-1B (IL-1B) by breast cancer cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Tulotta, Claudia, Lefley, Diane V., Moore, Charlotte K., Amariutei, Ana E., Spicer-Hadlington, Amy R., Quayle, Lewis A., Hughes, Russell O., Ahmed, Khawla, Cookson, Victoria, Evans, Catherine A., Vadakekolathu, Jayakumar, Heath, Paul, Francis, Sheila, Pinteaux, Emmanuel, Pockley, A. Graham, Ottewell, Penelope D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295314/
https://www.ncbi.nlm.nih.gov/pubmed/34290237
http://dx.doi.org/10.1038/s41523-021-00305-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295314/
https://www.ncbi.nlm.nih.gov/pubmed/34290237
http://dx.doi.org/10.1038/s41523-021-00305-w

Ejemplares similares